Approved for use through 04/30/2003, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute ( PROPING SAIPTO

Sheet

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 10/686,322

Filing Date October 14, 2003

First Named Inventor CHU, GILBERT

Art Unit 1634

Examiner Name

Attorney Docket Number STAN-277

U.S. PATENT DOCUMENTS							
Examiner Initials'	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> (if known)	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
		l us-					

			FOREIGI	N PATENT DO	CUMENTS				
Exam Initia		Cite No.¹	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>3</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	٦		
/	IC/		WO 01/84139	11-08-2001	TUSHER et al.				
							<u> </u>		
			OTHER PRIOR ART—NO						
Exam Initia		Cite No.	item (book, magazine, journal, sei	rial, symposium, cata	tille of the article (when appropriation, etc.), date, page(s), volume		T²		
/H	IC/		Barber et al., RELATINSHIP BETO OF PERIPHERAL BLOOD LYMPHO DAMAGE FOLLOWING RADIOTH 55:179-86	DCYTES AND T	THE EXPRESSION OF N	ORMAL TISSUE			
			Brock et al., IN VITRO RADIOSENSITIVITY AND NORMAL TISSUE DAMAGE, (2000), Radiother Oncol, 55:93-94						
لمعر			Crompton et al., ALTERED APOP INCREASED TOXICITY, (1999), I						
		• •	Johansen et al., RELATIONSHIP FIBROBLASTS AND THE EXPRES AND SKIN ERYTHEMA AFTER RA	SION OF SUBO	CUTANEOUS FIBROSIS,	TELANGIECTASIA,			
-		•	Peacock et al., CELL'ULAR RADIO CURATIVE RADIOTHERAPY, (200	SENSITIVITY 00), Radiother	AND COMPLICATION F Oncol, 55:173-8	ISK AFTER			
/	HC/		Russell et al., LOW PREDICTIVE FOR FIBROSIS DEVELOPMENT F (1998), Int J Radiat Biol, 73:661	OLLOWING RA	RINSIC FIBROBLAST F ADIOTHERAPY FOR BR	RADIOSENSITIVITY EAST CANCER,			

Examiner Signature	/Heather Calamita/	Date .	05/09/2007
Signature	mediter Galamita,	Considered	00/00/2001

EXAMINER: Initial if reference considered, whether or not citation is In conformance with MPEP 609. Oraw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality, is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, proparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known			
<i></i>	INFORMATION DISCLOSURE			Application Number	10/686,322	
					Filing Date	October 14, 2003
	STATEMENT BY API	PLIC.	ANT		First Named Inventor	CHU, GILBERT
					Group Art Unit	1634
	(use as many sheets as ne	ecessa	00)		Examiner Name	
Sheet	2	of	2	: 	Attorney Docket Number	STAN-277

		OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), authieber, city and/or country where published.	T²
/HC		Tibshirani et al., DIAGNOSIS OF MULTIPLE CANCER TYPES BY SHRUNKEN CENTROIDS OF GENE EXPRESSION, (2002) Proc. Natl. Acad. Sci. 99:6567-6572	
/HC	/	Tusher et al., SIGNIFICANCE ANALYSIS OF MICROARRAYS APPLIED TO THE IONIZING RADIATION RESPONSE, (2001), Proc. Natl. Acad. Sci., 98:5116-5121	
			7
e e e			
•			7.
<i>y</i> -			
	١		
/			
Examiner	7	/Heather Calamita/ Date 05/09/2007	

Examiner Signature	/Heather Calamita/	Date Considered	05/09/2007

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Approved for use through 04/30/2003, OMB 0651-0031

Considered

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMS control number.

stitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

Signature

Complete if Known					
Application Number	10/686,322				
Filing Date	October 14, 2003				
First Named Inventor	CHU, GILBERT				
Art Unit	1634				
Examiner Name					
Attorney Docket Number	STAN-277				

			U.S. PATENT	DOCUMENTS	
Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevan
Initials'	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Figures Appear
/HC/	<u> </u>	US- 2003/0165954 A1	09-04-2003	KATAGIRI et al.	
7HC7		US- 2004/0018527 A1	01-29-2004	CHANG et al.	
		US-			
		US-		- 0	
		US-			<u> </u>
	<u> </u>	US-			
		US-			
		US-			·
		US-			
		05.			
		US-			
		US.			-

		FOREIG	N PATENT DO	CUMENTS		
Examiner Initials'	Cite	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document		Т
			1			$\vdash$
						Ė
			·			
Examiner		/Heather Calamita/		Date	05/09/2007	

\*EXAMINER; Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.